Compare Stocks → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CALTNASDAQ:CPRXNASDAQ:PTGXNASDAQ:SYRSNASDAQ:ZFGN Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCALTCalliditas Therapeutics AB (publ)$19.50+0.3%$20.86$15.25▼$29.30$579.42M1.57,766 shs3,791 shsCPRXCatalyst Pharmaceuticals$14.89+1.4%$15.52$11.09▼$17.76$1.76B0.891.47 million shs772,215 shsPTGXProtagonist Therapeutics$25.15+2.0%$28.31$13.72▼$33.34$1.47B2.01691,328 shs461,248 shsSYRSSyros Pharmaceuticals$5.04-1.2%$6.04$2.09▼$8.17$134.72M1.74211,673 shs44,534 shsZFGNZafgen$6.44+1.7%$18.47$0.62▼$2.76$241.31M0.27360,199 shs144,013 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCALTCalliditas Therapeutics AB (publ)+3.78%+8.78%-9.77%-16.49%-21.18%CPRXCatalyst Pharmaceuticals-2.91%-4.30%-6.79%+2.73%-8.36%PTGXProtagonist Therapeutics-4.05%-2.22%-11.93%-1.08%+6.02%SYRSSyros Pharmaceuticals+0.59%+8.05%-18.40%-25.76%+61.90%ZFGNZafgen-2.01%-0.78%-12.08%+33.83%+40.35%Better than Bitcoin? The Biotech Stock with 46,751% Potential (Ad)4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>>MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCALTCalliditas Therapeutics AB (publ)2.1944 of 5 stars3.33.00.00.01.70.01.9CPRXCatalyst Pharmaceuticals4.9815 of 5 stars4.51.00.03.92.43.34.4PTGXProtagonist Therapeutics1.5993 of 5 stars3.51.00.00.02.62.50.0SYRSSyros Pharmaceuticals3.8468 of 5 stars3.51.00.04.31.13.30.6ZFGNZafgenN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCALTCalliditas Therapeutics AB (publ)2.50Moderate Buy$34.0074.35% UpsideCPRXCatalyst Pharmaceuticals3.00Buy$26.4377.49% UpsidePTGXProtagonist Therapeutics3.00Buy$36.0043.14% UpsideSYRSSyros Pharmaceuticals3.00Buy$14.33184.39% UpsideZFGNZafgenN/AN/AN/AN/ACurrent Analyst RatingsLatest CALT, CPRX, PTGX, ZFGN, and SYRS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/3/2024SYRSSyros PharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$13.004/1/2024SYRSSyros PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.003/27/2024CPRXCatalyst PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$29.003/22/2024CPRXCatalyst PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$34.003/14/2024CPRXCatalyst PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$34.003/14/2024CPRXCatalyst PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$27.003/7/2024CPRXCatalyst PharmaceuticalsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$23.003/1/2024CPRXCatalyst PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$27.00 ➝ $34.003/1/2024CPRXCatalyst PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$24.002/28/2024PTGXProtagonist TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$34.00 ➝ $37.002/28/2024PTGXProtagonist TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCALTCalliditas Therapeutics AB (publ)$1.21B0.48N/AN/A$1.06 per share18.40CPRXCatalyst Pharmaceuticals$398.20M4.41$2.03 per share7.35$3.30 per share4.51PTGXProtagonist Therapeutics$60M24.43N/AN/A$5.84 per share4.31SYRSSyros Pharmaceuticals$9.94M13.55N/AN/A$0.79 per share6.38ZFGNZafgenN/AN/AN/AN/A$1.35 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCALTCalliditas Therapeutics AB (publ)-$43.96M-$1.64N/A5.65N/A-38.72%-104.47%-26.75%5/21/2024 (Estimated)CPRXCatalyst Pharmaceuticals$71.41M$0.6124.416.830.8317.93%26.56%22.13%5/8/2024 (Confirmed)PTGXProtagonist Therapeutics-$78.96M-$1.49N/AN/AN/AN/A-27.49%-25.30%5/2/2024 (Estimated)SYRSSyros Pharmaceuticals-$164.57M-$5.76N/AN/AN/A-1,656.34%-227.91%-75.60%5/8/2024 (Estimated)ZFGNZafgen-$45.41M-$1.07N/A∞N/AN/A-51.34%-34.55%N/ALatest CALT, CPRX, PTGX, ZFGN, and SYRS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2024N/ACPRXCatalyst Pharmaceuticals$0.31N/A-$0.31N/AN/AN/A 3/27/2024Q4 2023SYRSSyros Pharmaceuticals-$1.23-$1.19+$0.04-$0.20$2.40 million$0.39 million2/28/2024Q4 2023CPRXCatalyst Pharmaceuticals$0.45$0.49+$0.04$0.67$105.78 million$110.57 million2/27/202412/31/2023PTGXProtagonist Therapeutics$0.05$0.44+$0.39$0.44$60.00 million$60.00 million2/21/202412/31/2023CALTCalliditas Therapeutics AB (publ)-$0.09-$0.07+$0.02-$0.06$36.24 million$42.45 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCALTCalliditas Therapeutics AB (publ)N/AN/AN/AN/AN/ACPRXCatalyst PharmaceuticalsN/AN/AN/AN/AN/APTGXProtagonist TherapeuticsN/AN/AN/AN/AN/ASYRSSyros PharmaceuticalsN/AN/AN/AN/AN/AZFGNZafgenN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCALTCalliditas Therapeutics AB (publ)2.893.133.08CPRXCatalyst PharmaceuticalsN/A2.882.68PTGXProtagonist TherapeuticsN/A16.7116.71SYRSSyros Pharmaceuticals2.073.953.95ZFGNZafgen0.266.566.56OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCALTCalliditas Therapeutics AB (publ)2.83%CPRXCatalyst Pharmaceuticals79.22%PTGXProtagonist Therapeutics98.63%SYRSSyros Pharmaceuticals91.47%ZFGNZafgen70.43%Insider OwnershipCompanyInsider OwnershipCALTCalliditas Therapeutics AB (publ)2.20%CPRXCatalyst Pharmaceuticals12.10%PTGXProtagonist Therapeutics5.00%SYRSSyros Pharmaceuticals10.45%ZFGNZafgen14.20%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCALTCalliditas Therapeutics AB (publ)19229.79 million29.14 millionOptionableCPRXCatalyst Pharmaceuticals167118.01 million103.73 millionOptionablePTGXProtagonist Therapeutics11258.28 million55.36 millionOptionableSYRSSyros Pharmaceuticals6826.73 million23.94 millionOptionableZFGNZafgen3837.47 millionN/ANot OptionableCALT, CPRX, PTGX, ZFGN, and SYRS HeadlinesSourceHeadlineDiagnosing Diabetes: Not So Simplemedscape.com - November 2 at 7:42 AMDo New Weight Loss Meds Mean the End of Bariatric Surgery?medscape.com - October 6 at 8:53 PMPrader-Willi syndromepharmaphorum.com - August 23 at 8:34 PMThe Omnipod 5 System: Trial Results From ENDO 2021medscape.com - August 4 at 8:12 PMBeta Cells From Stem Cells: Nearing a Cure for Type 1 Diabetes?medscape.com - July 5 at 5:09 PMOral Semaglutide Brings GLP-1s to Primary Caremedscape.com - May 20 at 8:49 PMClinical Trials - Different Phases of the trial News, Research and Latest Updatesmedindia.net - May 20 at 3:49 PMObesity Therapeutic Pipeline Analysis, 2023 Updates | Insights into ... - Digital Journalnews.google.com - May 12 at 2:12 PMWeight Loss and Obesity Management Market Insights With ... - Taiwan Newsnews.google.com - May 11 at 3:06 AMGlobal Methionine Aminopeptidase 2 Market Report 2023 by Trend ... - The Northwestern Examinernews.google.com - May 4 at 6:30 PMWeight Loss and Obesity Management Market May See a Big Move ... - Digital Journalnews.google.com - May 2 at 1:13 PMIronwood Pharmaceuticals: A Promising Outlook for Long-Term ... - Best Stocksnews.google.com - May 2 at 8:13 AMThe Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulationmedscape.com - April 29 at 8:09 PMFast Five Quiz: Type 2 Diabetes and Dyslipidemia - Medscape Referencenews.google.com - April 22 at 12:41 AMAnti-Obesity Drugs Market Size, Share, Economic Growth, Emerging ... - Digital Journalnews.google.com - April 20 at 9:32 AMAnti-Obesity Drugs Market Size, Analysis, Share, Research, Business Growth and Forecast to 2031 - openPRnews.google.com - April 14 at 8:21 AMNew ADA Standards: Promoting Healthmedscape.com - April 13 at 7:20 AMNew ADA Standards: Promoting Healthmedscape.com - April 13 at 7:20 AMAnti-Obesity Drugs Market Set to Register a CAGR of 16.10% and ... - GlobeNewswirenews.google.com - April 10 at 12:56 PMGlobal Weight Loss Therapeutics Professional Market 2023 (Exclusive Report) | Future Work Trend by 2030marketwatch.com - April 9 at 10:32 AMAnti-Obesity Drugs Market is expected to rise at A CAGR Of 16.1% during the forecast period 2023 to 2031: Grow - openPRnews.google.com - April 5 at 7:34 AMAnti-Obesity Drugs Market to grow at a CAGR of over 16.1% from 2023 to 2031, reveals Growth Plus Reports - openPRnews.google.com - March 22 at 11:43 AMIndian Anti-Obesity Drug Market 2023 : Projected to Deliver Greater Revenues during the Forecast Period 2028 - openPRnews.google.com - March 1 at 1:17 PMZafgen (ZFGN) Stock Skyrockets on Positive Obesity Drug Resultsthestreet.com - February 26 at 7:51 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCalliditas Therapeutics AB (publ)NASDAQ:CALTCalliditas Therapeutics AB (publ), a commercial-stage specialty pharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetic kidney disease. It also develops Budenofalk 3 mg oral capsules for the treatment of autoimmune hepatitis. The company was founded in 2004 and is headquartered in Stockholm, Sweden.Catalyst PharmaceuticalsNASDAQ:CPRXCatalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.Protagonist TherapeuticsNASDAQ:PTGXProtagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.Syros PharmaceuticalsNASDAQ:SYRSSyros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.ZafgenNASDAQ:ZFGNZafgen, Inc., a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders. It also develops ZGN-1258, a MetAP2 inhibitor for treatment of PWS. Zafgen, Inc. was founded in 2005 and is headquartered in Boston, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.